Brokers Issue Forecasts for EW Q1 Earnings

Edwards Lifesciences Co. (NYSE:EW - Free Report) - Equities research analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for Edwards Lifesciences in a note issued to investors on Wednesday, February 12th. William Blair analyst M. Andrew anticipates that the medical research company will post earnings of $0.65 per share for the quarter. The consensus estimate for Edwards Lifesciences' current full-year earnings is $2.56 per share. William Blair also issued estimates for Edwards Lifesciences' Q2 2026 earnings at $0.68 EPS, Q3 2026 earnings at $0.67 EPS and Q4 2026 earnings at $0.72 EPS.

EW has been the topic of several other reports. Sanford C. Bernstein upgraded Edwards Lifesciences from a "strong sell" rating to a "hold" rating in a research report on Monday, October 28th. Robert W. Baird lowered their target price on Edwards Lifesciences from $73.00 to $68.00 and set a "neutral" rating on the stock in a research report on Friday, October 25th. Evercore ISI lowered their target price on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a research report on Wednesday, February 12th. Barclays lifted their target price on Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research report on Thursday, February 13th. Finally, Piper Sandler lifted their target price on Edwards Lifesciences from $70.00 to $73.00 and gave the company a "neutral" rating in a research report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, Edwards Lifesciences presently has an average rating of "Hold" and an average price target of $79.95.

Edwards Lifesciences Stock Performance

NYSE EW traded down $0.52 on Friday, hitting $75.67. 4,937,936 shares of the company traded hands, compared to its average volume of 4,574,817. The company has a market capitalization of $44.63 billion, a price-to-earnings ratio of 10.92, a P/E/G ratio of 3.64 and a beta of 1.10. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The business's 50 day moving average price is $72.78 and its 200-day moving average price is $69.68. Edwards Lifesciences has a 52-week low of $58.93 and a 52-week high of $96.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 2,500 shares of the company's stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $74.08, for a total transaction of $185,200.00. Following the sale, the vice president now directly owns 23,189 shares in the company, valued at $1,717,841.12. This represents a 9.73 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Steven R. Loranger sold 5,739 shares of the company's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $76.42, for a total value of $438,574.38. Following the sale, the director now owns 60,372 shares in the company, valued at approximately $4,613,628.24. This trade represents a 8.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 26,489 shares of company stock valued at $2,002,829. Insiders own 1.29% of the company's stock.

Institutional Investors Weigh In On Edwards Lifesciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EW. Prosperity Consulting Group LLC lifted its position in Edwards Lifesciences by 3.6% during the 4th quarter. Prosperity Consulting Group LLC now owns 3,906 shares of the medical research company's stock worth $289,000 after acquiring an additional 134 shares during the period. Abacus Planning Group Inc. lifted its position in Edwards Lifesciences by 0.3% during the 4th quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company's stock worth $2,977,000 after acquiring an additional 140 shares during the period. Bowman & Co S.C. lifted its position in Edwards Lifesciences by 1.2% during the 4th quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company's stock worth $924,000 after acquiring an additional 148 shares during the period. Moors & Cabot Inc. lifted its position in Edwards Lifesciences by 0.3% during the 4th quarter. Moors & Cabot Inc. now owns 54,589 shares of the medical research company's stock worth $4,041,000 after acquiring an additional 152 shares during the period. Finally, Quadrant Capital Group LLC lifted its position in Edwards Lifesciences by 3.1% during the 4th quarter. Quadrant Capital Group LLC now owns 5,180 shares of the medical research company's stock worth $383,000 after acquiring an additional 156 shares during the period. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.